News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

|Videos|July 19, 2023

Optimizing Treatment Duration and Adverse Effect Management in Patients with NDMM

Author(s)Joselle Cook, MBBS, Mayo Clinic, Matthew James Pianko, MD

Dr. Cook and Dr. Pianko share their perspectives on optimizing treatment strategies for individual patients in order to maximize response and mitigate adverse events.

Episodes in this series

EP. 1 Goals of Therapy and Treatment Options for Patients with Transplant-Ineligible NDMM

EP. 1 Goals of Therapy and Treatment Options for Patients with Transplant-Ineligible NDMM

EP. 2 Clinical Implications from the MAIA and SWOG S0777 Studies

EP. 2 Clinical Implications from the MAIA and SWOG S0777 Studies

EP. 3 Assessing and Supporting Frail Patients with NDMM

EP. 3 Assessing and Supporting Frail Patients with NDMM

EP. 4 Implementing Real-world Evidence into Clinical Practice in NDMM

EP. 4 Implementing Real-world Evidence into Clinical Practice in NDMM

EP. 5 Optimizing Treatment Duration and Adverse Effect Management in Patients with NDMM

EP. 5 Optimizing Treatment Duration and Adverse Effect Management in Patients with NDMM

EP. 6 Addressing Unmet Needs and Disparities Across Patient Populations in Multiple Myeloma

EP. 6 Addressing Unmet Needs and Disparities Across Patient Populations in Multiple Myeloma

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

EP. 7 Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Trending on CancerNetwork

Spotlighting the Top 10 FDA Oncology Approvals in 2025

A Look Back on the Top 10 Oncology Interviews in 2025

Zovegalisib Combo Confers Efficacy Benefit in PIK3CA-Mutated Breast Cancer

What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting

‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer